Literature DB >> 7618802

Failure of methylprednisolone to improve the outcome of spinal cord injuries.

E R George1, D J Scholten, C M Buechler, J Jordan-Tibbs, C Mattice, R M Albrecht.   

Abstract

The infusion of methylprednisolone (MP) within 8 hours of injury for spinal cord injuries (SCI) has been advocated to improve the motor function of patients after this catastrophic injury. However, clinical improvement in the outcome of SCI has not been consistently identified, despite the use of MP. We reviewed the outcome of SCI patients with MP to those without MP (No-MP) at two Level I Trauma Centers from 1989-1992. Acute SCI patients were identified from the trauma registries with trauma demographics and hospital data obtained from registry and medical records. Rehabilitation data for Functional Independence Measure (FIM) was obtained from the rehabilitation institute database. Primary outcome parameters were mortality, and for survivors, patient mobility (6 point scale) and FIM scores. There were 145 acute SCI patients: 80 treated with MP and 65 with No-MP. FIM data was available on 45 MP and 25 No-MP patients. There was no difference in the admission trauma score, ICU length of stay (LOS), or hospital LOS between the two groups. The MP patients were significantly younger (30 years vs 38 years, P = < 0.05) and had lower ISS scores (24 vs 31, P = < 0.05). There was no statistically significant difference in mortality (MP, 3.8% vs No-MP, 10.7%) between the two groups. Although admission mobility was not statistically different (MP, 5.99 vs No-MP, 5.90), there was a significantly poorer discharge mobility in the MP group when compared to the No-MP group (MP, 5.16 vs No-MP, 4.67, P = < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7618802

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  12 in total

Review 1.  Chemical priming for spinal cord injury: a review of the literature part II-potential therapeutics.

Authors:  Martin M Mortazavi; Ketan Verma; Aman Deep; Fatemeh B Esfahani; Patrick R Pritchard; R Shane Tubbs; Nicholas Theodore
Journal:  Childs Nerv Syst       Date:  2010-12-21       Impact factor: 1.475

Review 2.  Chemical priming for spinal cord injury: a review of the literature. Part I-factors involved.

Authors:  Martin M Mortazavi; Ketan Verma; Aman Deep; Fatemeh B Esfahani; Patrick R Pritchard; R Shane Tubbs; Nicholas Theodore
Journal:  Childs Nerv Syst       Date:  2010-12-18       Impact factor: 1.475

Review 3.  A review: the role of high dose methylprednisolone in spinal cord trauma in children.

Authors:  Janine N Pettiford; Jai Bikhchandani; Daniel J Ostlie; Shawn D St Peter; Ronald J Sharp; David Juang
Journal:  Pediatr Surg Int       Date:  2011-10-13       Impact factor: 1.827

4.  Neuroprotective role of hydralazine in rat spinal cord injury-attenuation of acrolein-mediated damage.

Authors:  Jonghyuck Park; Lingxing Zheng; Andrew Marquis; Michael Walls; Brad Duerstock; Amber Pond; Sasha Vega-Alvarez; He Wang; Zheng Ouyang; Riyi Shi
Journal:  J Neurochem       Date:  2013-12-15       Impact factor: 5.372

5.  Effect of endogenous androgens on 17beta-estradiol-mediated protection after spinal cord injury in male rats.

Authors:  Supatra Kachadroka; Alicia M Hall; Tracy L Niedzielko; Sukumal Chongthammakun; Candace L Floyd
Journal:  J Neurotrauma       Date:  2010-03       Impact factor: 5.269

6.  Mobility criteria for upright sitting with patients in the neuro/trauma intensive care unit: an analysis of length of stay and functional outcomes.

Authors:  Bernadette T Gillick; Wendy J Marshall; Wendy Rheault; Judy Stoecker
Journal:  Neurohospitalist       Date:  2011-10

Review 7.  CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure.

Authors:  Michael T Fitch; Jerry Silver
Journal:  Exp Neurol       Date:  2007-05-31       Impact factor: 5.330

8.  Continuous brain-derived neurotrophic factor (BDNF) infusion after methylprednisolone treatment in severe spinal cord injury.

Authors:  Daniel H Kim; Tae-Ahn Jahng
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

9.  Mortality and morbidity after high-dose methylprednisolone treatment in patients with acute cervical spinal cord injury: a propensity-matched analysis using a nationwide administrative database.

Authors:  Hirotaka Chikuda; Hideo Yasunaga; Katsushi Takeshita; Hiromasa Horiguchi; Hiroshi Kawaguchi; Kazuhiko Ohe; Kiyohide Fushimi; Sakae Tanaka
Journal:  Emerg Med J       Date:  2013-02-28       Impact factor: 2.740

10.  Acrolein as a novel therapeutic target for motor and sensory deficits in spinal cord injury.

Authors:  Jonghyuck Park; Breanne Muratori; Riyi Shi
Journal:  Neural Regen Res       Date:  2014-04-01       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.